{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:42:16Z","timestamp":1777794136002,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2015-0776"],"award-info":[{"award-number":["2015-0776"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Dipartimenti di Eccellenza Program 2023\u20132027"],"award-info":[{"award-number":["Dipartimenti di Eccellenza Program 2023\u20132027"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","award":["PNRR-POC-2023-12377653"],"award-info":[{"award-number":["PNRR-POC-2023-12377653"]}],"id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNC-E3-2022-23683266"],"award-info":[{"award-number":["PNC-E3-2022-23683266"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Mutations in the\n                      <jats:italic>Immunoglobulin Mu DNA Binding Protein 2<\/jats:italic>\n                      (\n                      <jats:italic>IGHMBP2<\/jats:italic>\n                      ) gene cause Spinal Muscular Atrophy with Respiratory Distress type 1 (SMARD1), a rare, infantile, and fatal motor neuron disease, as well as the milder Charcot-Marie-Tooth disease type 2S (CMT2S). Gene therapy has emerged as a promising approach to correcting IGHMBP2 loss in SMARD1 models, but critical challenges remain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we compared the efficacy of two novel, optimized adeno-associated virus 9 (AAV9)-\n                      <jats:italic>IGHMBP2<\/jats:italic>\n                      vectors, utilizing either the Chicken \u03b2-Actin (CBA) or a truncated form of the methyl-CpG-binding protein 2 (MeCP2) promoter (P546), in the SMARD1 murine model via intracerebroventricular delivery. Treated mice survival, histopathological and molecular profile were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Corroborating previous findings, both constructs effectively rescued the pathological phenotype, significantly improving survival, body weight, and motor function while preserving motor neurons and neuromuscular junctions. Notably, histopathological and RNA sequencing analyses revealed, for the first time, inflammatory marker alterations in the SMARD1 spinal cord, which resolved following treatment. A comparative analysis of the two vectors demonstrated superior long-term efficacy of the P546-promoter construct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICV gene therapy approach can effectively rescue SMARD1 pathological hallmarks, including astrogliosis and microgliosis. Moreover, P546-promoter construct is superior in terms of safety profile and long-term therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-025-01204-z","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T07:52:53Z","timestamp":1767513173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AAV9 gene therapy optimization for SMARD1\/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model"],"prefix":"10.1186","volume":"33","author":[{"given":"Elisa","family":"Pagliari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriana","family":"Bellandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Garbellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Taiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ottoboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieth Andrea","family":"Sierra-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibi","family":"Likhite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Nizzardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania P.","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"1204_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ajmg.1320330309","volume":"33","author":"E Bertini","year":"1989","unstructured":"Bertini E, Gadisseux JL, Palmieri G, Ricci E, Capua MD, Ferriere G, et al. Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: a variant of infantile spinal muscular atrophy. Am J Med Genet. 1989;33:328\u201335. https:\/\/doi.org\/10.1002\/ajmg.1320330309.","journal-title":"Am J Med Genet"},{"key":"1204_CR2","unstructured":"Orphanet: Spinal muscular atrophy with respiratory distress type 1 https:\/\/www.orpha.net\/en\/disease\/detail\/98920."},{"key":"1204_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/ng703","volume":"29","author":"K Grohmann","year":"2001","unstructured":"Grohmann K, Schuelke M, Diers A, Hoffmann K, Lucke B, Adams C, et al. Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet. 2001;29:75\u20137. https:\/\/doi.org\/10.1038\/ng703.","journal-title":"Nat Genet"},{"key":"1204_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ajhg.2014.10.002","volume":"95","author":"E Cottenie","year":"2014","unstructured":"Cottenie E, Kochanski A, Jordanova A, Bansagi B, Zimon M, Horga A, et al. Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2. Am J Hum Genet. 2014;95:590\u2013601. https:\/\/doi.org\/10.1016\/j.ajhg.2014.10.002.","journal-title":"Am J Hum Genet"},{"key":"1204_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/hmg\/ddp134","volume":"18","author":"M de Planell-Saguer","year":"2009","unstructured":"de Planell-Saguer M, Schroeder DG, Rodicio MC, Cox GA, Mourelatos Z. Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. Hum Mol Genet. 2009;18:2115\u201326. https:\/\/doi.org\/10.1093\/hmg\/ddp134.","journal-title":"Hum Mol Genet"},{"key":"1204_CR6","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00018-020-03492-0","volume":"77","author":"MGL Perego","year":"2020","unstructured":"Perego MGL, Galli N, Nizzardo M, Govoni A, Taiana M, Bresolin N, et al. Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1). Cell Mol Life Sci CMLS. 2020;77:3351\u201367. https:\/\/doi.org\/10.1007\/s00018-020-03492-0.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"1204_CR7","volume-title":"Clinical pediatric neurology. A signs and symptoms approach","author":"GM Fenichel","year":"2001","unstructured":"Fenichel GM. Clinical pediatric neurology. A signs and symptoms approach. 4th ed. Saunders; 2001.","edition":"4"},{"key":"1204_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ana.10755","volume":"54","author":"K Grohmann","year":"2003","unstructured":"Grohmann K, Varon R, Stolz P, Schuelke M, Janetzki C, Bertini E, et al. Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Ann Neurol. 2003;54:719\u201324. https:\/\/doi.org\/10.1002\/ana.10755.","journal-title":"Ann Neurol"},{"key":"1204_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0883073807310989","volume":"23","author":"AM Kaindl","year":"2008","unstructured":"Kaindl AM, Guenther U-P, Rudnik-Sch\u00f6neborn S, Varon R, Zerres K, Schuelke M, et al. Spinal Muscular Atrophy With Respiratory Distress Type 1 (SMARD1). J Child Neurol. 2008;23:199\u2013204. https:\/\/doi.org\/10.1177\/0883073807310989.","journal-title":"J Child Neurol"},{"key":"1204_CR10","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1542\/peds.2011-0544","volume":"129","author":"M Eckart","year":"2012","unstructured":"Eckart M, Guenther U-P, Idkowiak J, Varon R, Grolle B, Boffi P, et al. The Natural Course of Infantile Spinal Muscular Atrophy With Respiratory Distress Type 1 (SMARD1). Pediatrics. 2012;129:e148\u201356. https:\/\/doi.org\/10.1542\/peds.2011-0544.","journal-title":"Pediatrics"},{"key":"1204_CR11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/hmg\/ddi189","volume":"14","author":"R Ruiz","year":"2005","unstructured":"Ruiz R, Lin J, Forgie A, Foletti D, Shelton D, Rosenthal A, et al. Treatment with trkC agonist antibodies delays disease progression in neuromuscular degeneration (nmd) mice. Hum Mol Genet. 2005;14:1825\u201337. https:\/\/doi.org\/10.1093\/hmg\/ddi189.","journal-title":"Hum Mol Genet"},{"key":"1204_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/brain\/awu059","volume":"137","author":"F Krieger","year":"2014","unstructured":"Krieger F, Elflein N, Saenger S, Wirthgen E, Rak K, Frantz S, et al. Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1. Brain. 2014;137:1374\u201393. https:\/\/doi.org\/10.1093\/brain\/awu059.","journal-title":"Brain"},{"key":"1204_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/hmg\/ddi446","volume":"15","author":"S Corti","year":"2006","unstructured":"Corti S, Locatelli F, Papadimitriou D, Donadoni C, Del Bo R, Crimi M, et al. Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1. Hum Mol Genet. 2006;15:167\u201387. https:\/\/doi.org\/10.1093\/hmg\/ddi446.","journal-title":"Hum Mol Genet"},{"key":"1204_CR14","doi-asserted-by":"publisher","first-page":"11761","DOI":"10.1523\/JNEUROSCI.2734-09.2009","volume":"29","author":"S Corti","year":"2009","unstructured":"Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Bo RD, et al. Motoneuron transplantation rescues the phenotype of SMARD1 (Spinal Muscular Atrophy with Respiratory Distress Type 1). J Neurosci. 2009;29:11761\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.2734-09.2009.","journal-title":"J Neurosci"},{"key":"1204_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/stem.471","volume":"28","author":"I Gutierrez-Aranda","year":"2010","unstructured":"Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, M\u00e1cia A, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010;28:1568\u201370. https:\/\/doi.org\/10.1002\/stem.471.","journal-title":"Stem Cells"},{"key":"1204_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102479","volume":"36","author":"S Smieszek","year":"2025","unstructured":"Smieszek S, Przychodzen B, Tyner C, Johnson C, Bai H, Kwon JM, et al. Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S. Mol Ther Nucleic Acids. 2025;36:102479. https:\/\/doi.org\/10.1016\/j.omtn.2025.102479.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1204_CR17","unstructured":"EMA. Zolgensma. Eur. Med. Agency. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma."},{"key":"1204_CR18","unstructured":"Zolgensma | FDA. FDA. 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"1204_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2014.00042","author":"DJ Schuster","year":"2014","unstructured":"Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014. https:\/\/doi.org\/10.3389\/fnana.2014.00042.","journal-title":"Front Neuroanat"},{"key":"1204_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen G, Burghes AHM, Hsieh C, Do J, Chu BTT, Perry S, et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021;27:1701\u201311. https:\/\/doi.org\/10.1038\/s41591-021-01483-7.","journal-title":"Nat Med"},{"key":"1204_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500078","volume":"1","author":"M Nizzardo","year":"2015","unstructured":"Nizzardo M, Simone C, Rizzo F, Salani S, Dametti S, Rinchetti P, et al. Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Sci Adv. 2015;1:e1500078. https:\/\/doi.org\/10.1126\/sciadv.1500078.","journal-title":"Sci Adv"},{"key":"1204_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/mt.2016.33","volume":"24","author":"M Shababi","year":"2016","unstructured":"Shababi M, Feng Z, Villalon E, Sibigtroth CM, Osman EY, Miller MR, et al. Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent. Mol Ther J Am Soc Gene Ther. 2016;24:855\u201366. https:\/\/doi.org\/10.1038\/mt.2016.33.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1204_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.omtm.2018.08.005","volume":"10","author":"M Shababi","year":"2018","unstructured":"Shababi M, Villal\u00f3n E, Kaifer KA, DeMarco V, Lorson CL. A direct comparison of IV and ICV delivery methods for gene replacement therapy in a mouse model of SMARD1. Mol Ther Methods Clin Dev. 2018;10:348\u201360. https:\/\/doi.org\/10.1016\/j.omtm.2018.08.005.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1204_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.omtm.2021.07.008","volume":"23","author":"M Shababi","year":"2021","unstructured":"Shababi M, Smith CE, Ricardez Hernandez SM, Marquez J, Al Rawi Z, Villal\u00f3n E, et al. Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB\/NJ-Ighmpb2 nmd-2J. Mol Ther Methods Clin Dev. 2021;23:23\u201332. https:\/\/doi.org\/10.1016\/j.omtm.2021.07.008.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1204_CR25","unstructured":"Waldrop, M. (2023). Phase I\/IIa Intrathecal Gene Delivery Clinical Trial for IGHMBP2-Related Diseases (clinicaltrials.gov)."},{"key":"1204_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1118649","author":"TB Johnson","year":"2023","unstructured":"Johnson TB, Brudvig JJ, Likhite S, Pratt MA, White KA, Cain JT, et al. Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease. Front Genet. 2023. https:\/\/doi.org\/10.3389\/fgene.2023.1118649.","journal-title":"Front Genet"},{"key":"1204_CR27","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/j.ymthe.2023.07.013","volume":"31","author":"S Powers","year":"2023","unstructured":"Powers S, Likhite S, Gadalla KK, Miranda CJ, Huffenberger AJ, Dennys C, et al. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates. Mol Ther. 2023;31:2767\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.013.","journal-title":"Mol Ther"},{"key":"1204_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"1204_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymthe.2020.09.033","volume":"29","author":"TB Johnson","year":"2021","unstructured":"Johnson TB, White KA, Brudvig JJ, Cain JT, Langin L, Pratt MA, et al. AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease. Mol Ther J Am Soc Gene Ther. 2021;29:162\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.033.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1204_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/hmg\/ddab317","volume":"31","author":"CE Smith","year":"2022","unstructured":"Smith CE, Lorson MA, Ricardez Hernandez SM, Al Rawi Z, Mao J, Marquez J, et al. The Ighmbp2D564N mouse model is the first SMARD1 model to demonstrate respiratory defects. Hum Mol Genet. 2022;31:1293\u2013307. https:\/\/doi.org\/10.1093\/hmg\/ddab317.","journal-title":"Hum Mol Genet"},{"key":"1204_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104870","volume":"140","author":"E Abati","year":"2020","unstructured":"Abati E, Citterio G, Bresolin N, Comi GP, Corti S. Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol Dis. 2020;140:104870. https:\/\/doi.org\/10.1016\/j.nbd.2020.104870.","journal-title":"Neurobiol Dis"},{"key":"1204_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s0896-6273(00)80652-2","volume":"21","author":"GA Cox","year":"1998","unstructured":"Cox GA, Mahaffey CL, Frankel WN. Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele. Neuron. 1998;21:1327\u201337. https:\/\/doi.org\/10.1016\/s0896-6273(00)80652-2.","journal-title":"Neuron"},{"key":"1204_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/hmg\/ddh129","volume":"13","author":"TP Maddatu","year":"2004","unstructured":"Maddatu TP, Garvey SM, Schroeder DG, Hampton TG, Cox GA. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum Mol Genet. 2004;13:1105\u201315. https:\/\/doi.org\/10.1093\/hmg\/ddh129.","journal-title":"Hum Mol Genet"},{"key":"1204_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mus.26329","volume":"58","author":"GA Meyer","year":"2018","unstructured":"Meyer GA. Evidence of induced muscle regeneration persists for years in the mouse. Muscle Nerve. 2018;58:858\u201362. https:\/\/doi.org\/10.1002\/mus.26329.","journal-title":"Muscle Nerve"},{"key":"1204_CR35","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestr\u00e9e N, Recinos Y, Workman E, Shihabuddin LS, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930\u201340. https:\/\/doi.org\/10.1038\/s41593-021-00827-3.","journal-title":"Nat Neurosci"},{"key":"1204_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8:359. https:\/\/doi.org\/10.1038\/s41392-023-01588-0.","journal-title":"Signal Transduct Target Ther"},{"key":"1204_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","volume":"24","author":"AN Brandebura","year":"2023","unstructured":"Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci. 2023;24:23\u201339. https:\/\/doi.org\/10.1038\/s41583-022-00641-1.","journal-title":"Nat Rev Neurosci"},{"key":"1204_CR38","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1002\/jcp.29682","volume":"235","author":"BL Tang","year":"2020","unstructured":"Tang BL. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol. 2020;235:7653\u201362. https:\/\/doi.org\/10.1002\/jcp.29682.","journal-title":"J Cell Physiol"},{"key":"1204_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2709-7","volume":"588","author":"J Zhang","year":"2020","unstructured":"Zhang J, Velmeshev D, Hashimoto K, Huang Y-H, Hofmann JW, Shi X, et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature. 2020;588:459\u201365. https:\/\/doi.org\/10.1038\/s41586-020-2709-7.","journal-title":"Nature"},{"key":"1204_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nbd.2018.11.013","volume":"124","author":"KJ Spiller","year":"2019","unstructured":"Spiller KJ, Khan T, Dominique MA, Restrepo CR, Cotton-Samuel D, Levitan M, et al. Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiol Dis. 2019;124:133\u201340. https:\/\/doi.org\/10.1016\/j.nbd.2018.11.013.","journal-title":"Neurobiol Dis"},{"key":"1204_CR41","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cne.24040","volume":"524","author":"CS von Bartheld","year":"2016","unstructured":"von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol. 2016;524:3865\u201395. https:\/\/doi.org\/10.1002\/cne.24040.","journal-title":"J Comp Neurol"},{"key":"1204_CR42","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.1038\/s41598-022-11204-w","volume":"12","author":"A Matsuyama","year":"2022","unstructured":"Matsuyama A, Kalargyrou AA, Smith AJ, Ali RR, Pearson RA. A comprehensive atlas of Aggrecan, Versican, Neurocan and Phosphacan expression across time in wildtype retina and in retinal degeneration. Sci Rep. 2022;12:7282. https:\/\/doi.org\/10.1038\/s41598-022-11204-w.","journal-title":"Sci Rep"},{"key":"1204_CR43","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1093\/hmg\/ddi349","volume":"14","author":"TP Maddatu","year":"2005","unstructured":"Maddatu TP, Garvey SM, Schroeder DG, Zhang W, Kim S-Y, Nicholson AI, et al. Dilated cardiomyopathy in the nmd mouse: transgenic rescue and QTLs that improve cardiac function and survival. Hum Mol Genet. 2005;14:3179\u201389. https:\/\/doi.org\/10.1093\/hmg\/ddi349.","journal-title":"Hum Mol Genet"},{"key":"1204_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000007039","volume":"94","author":"J Finsterer","year":"2000","unstructured":"Finsterer J, St\u00f6llberger C. Cardiac involvement in primary myopathies. Cardiology. 2000;94:1\u201311. https:\/\/doi.org\/10.1159\/000007039.","journal-title":"Cardiology"},{"key":"1204_CR45","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1093\/hmg\/ddi402","volume":"14","author":"M Adachi","year":"2005","unstructured":"Adachi M, Keefer EW, Jones FS. A segment of the Mecp2 promoter is sufficient to drive expression in neurons. Hum Mol Genet. 2005;14:3709\u201322. https:\/\/doi.org\/10.1093\/hmg\/ddi402.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1204_CR46","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s44321-024-00037-x","volume":"16","author":"Q Xie","year":"2024","unstructured":"Xie Q, Chen X, Ma H, Zhu Y, Ma Y, Jalinous L, et al. Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor. EMBO Mol Med. 2024;16(4):945\u201365. https:\/\/doi.org\/10.1038\/s44321-024-00037-x.","journal-title":"EMBO Mol Med"},{"key":"1204_CR47","unstructured":"https:\/\/www.jax.org\/strain\/002521."},{"key":"1204_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0160-5402(86)90038-0","volume":"16","author":"SE Laursen","year":"1986","unstructured":"Laursen SE, Belknap JK. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods. 1986;16:355\u20137. https:\/\/doi.org\/10.1016\/0160-5402(86)90038-0.","journal-title":"J Pharmacol Methods"},{"key":"1204_CR49","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.ymthe.2021.11.012","volume":"30","author":"M Bersani","year":"2022","unstructured":"Bersani M, Rizzuti M, Pagliari E, Garbellini M, Saccomanno D, Moulton HM, et al. Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model. Mol Ther. 2022;30:1288\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.012.","journal-title":"Mol Ther"},{"key":"1204_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0006-8993(95)00463-Z","volume":"686","author":"I Jalenques","year":"1995","unstructured":"Jalenques I, Albuisson E, Despres G, Romand R. Distribution of glial fibrillary acidic protein (GFAP) in the cochlear nucleus of adult and aged rats. Brain Res. 1995;686:223\u201332. https:\/\/doi.org\/10.1016\/0006-8993(95)00463-Z.","journal-title":"Brain Res"},{"key":"1204_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","volume":"36","author":"M Nizzardo","year":"2014","unstructured":"Nizzardo M, Simone C, Salani S, Ruepp M-D, Rizzo F, Ruggieri M, et al. Effect of combined systemic and local Morpholino treatment on the spinal muscular atrophy \u03947 mouse model phenotype. Clin Ther. 2014;36:340-356.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.004.","journal-title":"Clin Ther"},{"key":"1204_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217918","volume":"21","author":"A DeChick","year":"2020","unstructured":"DeChick A, Hetz R, Lee J, Speelman DL. Increased skeletal muscle fiber cross-sectional area, muscle phenotype shift, and altered insulin signaling in rat hindlimb muscles in a prenatally androgenized rat model for polycystic ovary syndrome. Int J Mol Sci. 2020;21:7918. https:\/\/doi.org\/10.3390\/ijms21217918.","journal-title":"Int J Mol Sci"},{"key":"1204_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00018-024-05550-3","volume":"82","author":"E Pagliari","year":"2024","unstructured":"Pagliari E, Taiana M, Manzini P, Sali L, Quetti L, Bertolasi L, et al. Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models. Cell Mol Life Sci. 2024;82:29. https:\/\/doi.org\/10.1007\/s00018-024-05550-3.","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01204-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T07:52:55Z","timestamp":1767513175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-025-01204-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01204-z","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures received approval from the Institutional Animal Care and Use Committee (IACUC) of the University of Milan and the Italian Ministry of Health, adhering to national guidelines (D.I. no. 116, G.U. supplement 40, February 18th, 1992; Circular no. 8, G.U., July 14th, 1994) under the approved protocol 707\/2019-PR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.N, S.C. and K.M. are inventor of the international patent PCT\/US20\/61863: \u201cAAV Gene Therapy for Spinal Muscular Atrophy with Respiratory Distress Type I (SMARD1; OMIN 604320) and Charcot-Marie-Tooth Disease 2S (CMT2S) Caused by Mutations in the IGHMBP2 Gene\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}